about
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.Chronic lymphocytic leukemia: Time to go past genomics?Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea.Human Herpesvirus 6 (HHV-6) necrotizing encephalitis, a rare condition in immunocompromised patients: The importance of brain biopsy associated with HHV-6 testing.Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.Central diabetes insipidus revealing neuromeningeal localization of chronic myelomonocytic leukaemia.14q deletions are associated with trisomy 12,NOTCH1mutations and unmutatedIGHVgenes in chronic lymphocytic leukemia and small lymphocytic lymphomaMutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working groupTherapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusionsStem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow TransplantationGraft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantationNatural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantationAre myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances ProliferationConstitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemiaPostallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumabCarfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialGain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemiaIbrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO groupPrevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
P50
Q33593133-D3A19AA9-EA6E-4968-A59B-B8FEBA129809Q34293019-3BA5D0DC-2874-40BE-AE0D-9F21A5D95D92Q35265979-B4E7E80D-C53A-4386-8C91-EA4995C50D20Q36150869-BFA7FF73-5C0C-4727-A320-7FBD9087987CQ37853787-85C08A4D-182F-4512-9798-E8E365916DEFQ38692332-2932AA76-4203-42C0-8DB9-B7A3EA16E274Q38708220-BEB9351A-028F-4BFF-A8FE-6B374839C061Q38752592-514B5009-07B7-4AE7-83F1-82F0E84D3420Q39014264-9200870A-AC1D-45FA-A405-42E6BF9352B4Q39349837-6E119439-9C7B-4114-A573-9C2108030AEBQ40455172-368E6E02-FA6D-43C1-8043-FBB53D52167EQ42660670-0A057BF0-04A7-4E45-B9DF-06D3B73D8125Q42910856-1391F2B3-3C22-4408-8DEA-547AC300F8D0Q45148365-C40CF86F-42A3-4D69-B1E8-AE5076D914C2Q47787958-75FA4FF1-4222-4D7D-B4B9-F877A9323D9BQ50947793-10F50049-BA61-488F-8EA3-21FA45338D45Q51630818-07E1E557-6163-4793-9AA3-EC50AE23DA94Q53746177-648D5DAC-85D0-47C8-B9A5-9E6647C98F2DQ54781002-98C6D03B-71DA-4F95-BD8F-6AFA81DDCB3BQ58041694-99A6B126-C93A-488B-82A2-08D88AA29BB5Q61772114-103EFA19-C441-48B0-A196-CBF0106E8A7BQ61772124-8F471A1B-B1D7-4F8A-AAE1-CCA1B00F7571Q85591188-2CE80C14-F31B-4F73-8195-47201F6FF93BQ85899518-3A0FC1AE-6A75-4F63-B21C-677FDF04969CQ86190982-16E6CBEF-C4BC-47EF-B463-F2A0AAA2188EQ88401638-A8124B6E-2C37-4C3C-91E7-356B6328F284Q90281817-A0E5E3D2-8567-4A34-BBE0-6DD83B80770DQ90710875-45FB6784-4161-42BB-9C60-F7A9DC323DB4Q91661771-E4A39DB0-AEEE-44BF-9C7E-31F3CE5DC4ACQ91750643-C35598DD-43B3-4173-99FA-0AE216DA6FBBQ91843311-FEB00BB5-5BE0-4E7C-A0E4-2081DE3B7390Q92838115-3FE1C484-83E9-4A6B-B3F2-AF80B5D59E83Q93051331-C7BA7DFA-1D53-496D-B767-ED4C87BAC1F9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Damien Roos-Weil
@ast
Damien Roos-Weil
@en
Damien Roos-Weil
@es
Damien Roos-Weil
@nl
type
label
Damien Roos-Weil
@ast
Damien Roos-Weil
@en
Damien Roos-Weil
@es
Damien Roos-Weil
@nl
prefLabel
Damien Roos-Weil
@ast
Damien Roos-Weil
@en
Damien Roos-Weil
@es
Damien Roos-Weil
@nl
P106
P31
P496
0000-0002-7767-755X